CNBX Pharmaceuticals Inc. financial data

Symbol
CNBX on OTC
Industry
Pharmaceutical Preparations
Location
#3 Bethesda Metro Center, Suite 700, Bethesda, MD
State of incorporation
NV
Fiscal year end
August 31
Former names
Cannabics Pharmaceuticals Inc. (to 3/16/2022), American Mining Corp (to 5/1/2014), Thrust Energy Corp. (to 5/10/2011)
Latest financial report
10-Q - Q2 2024 - Jul 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 6.16 % -17.9%
Return On Equity 54.2 % -71.8%
Return On Assets -428 % +24.8%
Operating Margin -301 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.1M shares +82.6%
Common Stock, Shares, Outstanding 3.11M shares -80.6%
Entity Public Float 438K USD -75.8%
Common Stock, Value, Issued 3.11K USD +94.1%
Weighted Average Number of Shares Outstanding, Basic 31.1M shares +236%
Weighted Average Number of Shares Outstanding, Diluted 31.1M shares +236%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 230K USD -100%
Cost of Revenue 6.22K USD
Research and Development Expense 356K USD -29.1%
General and Administrative Expense 560K USD -48.4%
Operating Income (Loss) -692K USD +44.6%
Net Income (Loss) Attributable to Parent -1.21M USD +66.6%
Earnings Per Share, Basic 1.25 USD/shares
Earnings Per Share, Diluted 1.25 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 73.4K USD +66.3%
Assets, Current 80K USD -77.1%
Property, Plant and Equipment, Net 0 USD -100%
Assets 80K USD -87.9%
Liabilities, Current 2.53M USD -1.44%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -24.9M USD -5.1%
Stockholders' Equity Attributable to Parent -2.45M USD -28.5%
Liabilities and Equity 80K USD -87.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -71.8K USD +25.1%
Net Cash Provided by (Used in) Financing Activities 25K USD
Net Cash Provided by (Used in) Investing Activities -1.2K USD
Common Stock, Shares Authorized 900M shares 0%
Common Stock, Shares, Issued 3.11M shares -80.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 73.4K USD +66.3%
Deferred Tax Assets, Valuation Allowance 5.98M USD +11.2%
Depreciation 39.5K USD -8.62%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.15M USD +69.3%
Deferred Tax Assets, Operating Loss Carryforwards 5.98M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares -95%
Additional Paid in Capital 22.4M USD +20.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%